Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunic, Inc. (IMUX : NSDQ)

• Company Description    Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $13.05 Daily Weekly Monthly 20 Day Moving Average: 288,888 shares Shares Outstanding: 13.62 (millions) Market Capitalization: $177.77 (millions) Beta: 1.20 52 Week High: $15.10 52 Week Low: $5.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 42.11% 35.17% 12 Week 37.70% 27.30% Year To Date 144.52% 111.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1200 AVENUE SUITE 200 - NEW YORK,NY 10036 USA ph: 332-255-9818 fax: 858-673-6843 jessica.breu@imux.com http://www.immunic-therapeutics.com

• General Corporate Information    Officers Daniel Vitt - Chief Executive Officer;Director; Simona Skerjanec - Chair of the Board of Director Glenn Whaley - Chief Financial Officer Duane D. Nash - Director Tamar Howson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 4525EP200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 13.62 Most Recent Split Date: 4.00 (0.10:1) Beta: 1.20 Market Capitalization: $177.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.18 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 56.80% vs. Previous Quarter: 10.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -220.75 12/31/25 - -1,197.81 09/30/25 - -716.20 ROA 03/31/26 - -132.04 12/31/25 - -264.95 09/30/25 - -252.08 Current Ratio 03/31/26 - 4.92 12/31/25 - 0.75 09/30/25 - 1.31 Quick Ratio 03/31/26 - 4.92 12/31/25 - 0.75 09/30/25 - 1.31 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 11.10 12/31/25 - -0.55 09/30/25 - 1.06 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - - 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - - 09/30/25 - 0.00

Powered by Zacks Investment Research ©